Feinstein Institute for Medical Research

Running trials

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

  NCT06808984· Phase 2· Celgene· Source

• Recruiting

  Biomarkers to Enhance Early Schizophrenia Treatment

  NCT06969755· Phase 4· Northwell Health· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting
• Schizophrenia1 recruiting

Closed trials

• Terminated

  A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

  NCT05744401· Phase 2· Alector Inc.· Source

• Terminated

  COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

  NCT05000216· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

  NCT02633163· Phase 2· Medical University of South Carolina· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Schizophrenia61 works · 1 trial
• Lupus (SLE)25 works · 2 trials